|
1
|
Shore RN, Shore P, Monahan NM and Sundeen
J: Serial screening for melanoma: Measures and strategies that have
consistently achieved early detection and cure. J Drugs Dermatol.
10:244–252. 2011.PubMed/NCBI
|
|
2
|
Boyle GM: Therapy for metastatic melanoma:
An overview and update. Expert Rev Anticancer Ther. 11:725–737.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
MacKie RM, Hauschild A and Eggermont AM:
Epidemiology of invasive cutaneous melanoma. Ann Oncol. 20 (Suppl
6):vi1–vi7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Houghton AN and Polsky D: Focus on
melanoma. Cancer Cell. 2:275–278. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hollier BG, Evans K and Mani SA: The
epithelial-to-mesenchymal transition and cancer stem cells: A
coalition against cancer therapies. J Mammary Gland Biol Neoplasia.
14:29–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu MY, Meier FE, Nesbit M, Hsu JY, Van
Belle P, Elder DE and Herlyn M: E-cadherin expression in melanoma
cells restores keratinocyte-mediated growth control and
down-regulates expression of invasion-related adhesion receptors.
Am J Pathol. 156:1515–1525. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ben Sahra I, Le Marchand-brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: A new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pollak M: Metformin and other biguanides
in oncology: Advancing the research agenda. Cancer Prev Res
(Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: A
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar
|
|
14
|
Woodard J and Platanias LC: AMP-activated
kinase (AMPK)-generated signals in malignant melanoma cell growth
and survival. Biochem Biophys Res Commun. 398:135–139. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Janjetovic K, Harhaji-Trajkovic L,
Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N,
Sumarac-Dumanovic M, Micic D and Trajkovic V: In vitro and
in vivo anti-melanoma action of metformin. Eur J Pharmacol.
668:373–382. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niehr F, von EE, Attar N, Guo D, Matsunaga
D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, et al: Combination
therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma
cell lines with distinct driver mutations. J Transl Med. 9:762011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tomic T, Botton T, Cerezo M, Robert G,
Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder
JM, et al: Metformin inhibits melanoma development through
autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cerezo M, Tichet M, Abbe P, Ohanna M,
Lehraiki A, Rouaud F, Allegra M, Giacchero D, Bahadoran P,
Bertolotto C, et al: Metformin blocks melanoma invasion and
metastasis development in AMPK/p53-dependent manner. Mol Cancer
Ther. 12:1605–1615. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Andújar-Plata P, Pi-Sunyer X and Laferrère
B: Metformin effects revisited. Diabetes Res Clin Pract. 95:1–9.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cerezo M, Tomic T, Ballotti R and Rocchi
S: Is it time to test biguanide metformin in the treatment of
melanoma? Pigment Cell Melanoma Res. 28:8–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo
through a decrease of cyclin D1 level. Oncogene. 27:3576–3586.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Algire C, Zakikhani M, Blouin MJ, Shuai JH
and Pollak M: Metformin attenuates the stimulatory effect of a
high-energy diet on in vivo LLC1 carcinoma growth. Endocr
Relat Cancer. 15:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and
Xu GM: Metformin induces apoptosis of pancreatic cancer cells.
World J Gastroenterol. 14:7192–7198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takeichi M: Cadherins in cancer:
Implications for invasion and metastasis. Curr Opin Cell Biol.
5:806–811. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Christofori G and Semb H: The role of the
cell-adhesion molecule E-cadherin as a tumour-suppressor gene.
Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rattan R, Ali Fehmi R and Munkarah A:
Metformin: An emerging new therapeutic option for targeting cancer
stem cells and metastasis. J Oncol. 2012:9281272012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sarrió D, Rodriguez-Pinilla SM, Hardisson
D, Cano A, Moreno-Bueno G and Palacios J: Epithelial-mesenchymal
transition in breast cancer relates to the basal-like phenotype.
Cancer Res. 68:989–997. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Birchmeier W and Behrens J: Cadherin
expression in carcinomas: role in the formation of cell junctions
and the prevention of invasiveness. Biochim Biophys Acta.
1198:11–26. 1994.PubMed/NCBI
|
|
32
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–148.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Perl AK, Wilgenbus P, Dahl U, Semb H and
Christofori G: A causal role for E-cadherin in the transition from
adenoma to carcinoma. Nature. 392:190–193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nakamura M and Tokura Y:
Epithelial-mesenchymal transition in the skin. J Dermatol Sci.
61:7–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang A, Eller MS, Hara M, Yaar M,
Hirohashi S and Gilchrest BA: E-cadherin is the major mediator of
human melanocyte adhesion to keratinocytes in vitro. J Cell
Sci. 107:983–992. 1994.PubMed/NCBI
|
